Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$0.60
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-4.1M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$175M
P/E
N/A
•EV/EBITDA
N/A
•ROE
70.9%
↑Gross Margin
N/A
•Debt/Equity
-0.59
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+47.1%
FCF CAGR
—
FCF margin
-1188.2%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $363000.0 · net income $-4.7M · FCF $-4.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $363000.00 | $363000.00 | $719000.00 | $291000.00 | $114000.00 |
| Net Income | $-4.7M | $-4.7M | $-4.5M | $-25.0M | $-36.4M |
| EBITDA | $-4.3M | $-4.3M | $-4.3M | $-7.7M | $-9.6M |
| EPS | -0.02 | -0.02 | -0.02 | -0.11 | -0.30 |
| Gross Margin | — | — | -295.0% | -836.1% | -2500.0% |
| Operating Margin | -1183.7% | -1183.7% | -582.6% | -9608.6% | -26977.2% |
| Net Margin | -1297.5% | -1297.5% | -623.4% | -8607.9% | -31953.5% |
| Balance Sheet | |||||
| Debt/Equity | -0.59 | -0.59 | -0.57 | -0.77 | 5.29 |
| Current Ratio | 0.08 | 0.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.3M | $-4.3M | $-4.1M | $-3.8M | $494000.00 |
| Returns | |||||
| ROE | 70.9% | 70.9% | 76.0% | 1615.0% | -1402.7% |
| Valuation | |||||
| P/B | — | — | — | — | 73.00 |
| Growth & Yield | |||||
| Revenue Growth | -49.5% | -49.5% | 147.1% | 155.3% | — |
| EPS Growth | 8.2% | 8.2% | 82.4% | 63.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.02
Residual
-41.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.